Skip to main content

Tweets

Global prevalence of juvenile idiopathic arthritis is ~ 2,069,246 < 16 year olds compared with a prevalence of ~ 206,931 < 16 year olds with juvenile SLE. JIA is 10 times more prevalent than lupus in children < 16yrs. https://t.co/2xvhg59c1J

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
RECOVERY RCT, dexamethasone vs usual care in COVID19 ⬇️28d mortality in pts on O2 (21.5% vs 25%, NNT ~22) or IMV (29% vs 41%, NNT~8)... ?⬆️ for pts w/out O2 1. Preprint*️⃣ 2. No blinding, but hard outcome & meaningful benefit Will likely be adopted, kudos 🇬🇧 for a useful RCT! https://t.co/m5OAYMIvZy
Mike Putman EBRheum( View Tweet)
1 month 1 week ago
If you treat #SLE patients, Do you get a renal biopsy before starting therapy for Lupus nephritis?

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
High uric acid is associated with a higher risk of kidney cancer, especially in women; Data from a UK biobank of 444 462 without cancer w/ 6.5 yrs F/U. Highest Urate quartile had increased risk of renal cancer (HR 1.45, 95%CI 1.08 to 1.93), only in women. https://t.co/APWxFkewoF

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
The RheumNow Podcast is Up! Lupus Mortality Declines, But… Review of SUA and cancer; IL-12/23 and SLE; TCZ and Behcets, Pregnancy SI MRI, VTE w/ Jaks; COVID; Colchicine. Watch it here> https://t.co/2V7TbaAsOp or listen on iTunes or SoundCloud https://t.co/XMps2GTgeD

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
Retrospective study of 2369 patients with Kawasaki disease examined different doses of aspirin showing lower ASA doses of 20–29 mg/kg/day was as effective as 30–50 mg/kg/day in preventing coronary artery aneurysms with no change in IVIG resistance https://t.co/kJgkSSpjyw

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
J&J announced that is discontinuing its phase 3 trial of ustekinumab in #SLE. An interim analysis of the 516 pt LOTUS trial showed no new safety concerns. Study was halted for lack of efficacy. A subsequent LOTUS-C trial in China has been suspended. https://t.co/iN5trI0V71

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
Study of 1362 #RA patients given TNF inhibitors, abatacept, tocilizumab between 2011-17 finds TCZ had best survival regardless of age; ABA had lowest D/C for adverse events & disease activity improved more with TNFi. https://t.co/7RRO9M4Wf0

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
Tocilizumab may be effective in refractory ocular-, neuro-, vasculo-Behcet's. Study of 47 Behcet's pts Rx w/ TCZ - good at ocular (24/25), CNS (6/6), vascular (7/7) & amyloidosis(2/2) but less effective w/ oral/genital (8/21), skin (6/14) or joints (4/11) https://t.co/lKY8D706bi

Dr. John Cush RheumNow( View Tweet)

1 month 2 weeks ago
TNFi, ABA, TCZ Retention rates looked at in 1362 RA according to age. For < 65 years, 3-year retention was best for TCZ 69%. For pts 65–74 years, retention rates highest for TCZ . For ≥ 75 years, 3-year retention rates best for ABA & TCZ (63% & 58%). https://t.co/7RRO9M4Wf0

Dr. John Cush RheumNow( View Tweet)

1 month 2 weeks ago
Comparison of elderly-onset (>60yrs) #RA (EORA) to younger-onset (YORA) finds significantly more treatment resistant synovitis and Xray progression in EORA pts with worse overall prognosis compared to YORA (clinical, UA, and pathology). https://t.co/17XSz3Ilap

Dr. John Cush RheumNow( View Tweet)

1 month 2 weeks ago
Metanalysis of 8 studies and >130,000 patients shows that IBD (Crohns & UC) have a significantly higher risk of developing #RA (RR = 2.59; 95% CI: 1.93–3.48). https://t.co/ipYRZ6DQPQ

Dr. John Cush RheumNow( View Tweet)

1 month 2 weeks ago
×